Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients.

Mario Giuliano(Regione Campania), James M. Reuben(The University of Texas MD Anderson Cancer Center), Massimo Cristofanilli(Cornell University), R. H. Alvarez, Antonia Patt, V. Valero, Naoto T. Ueno(Breast Cancer Care), Lin-Kang Hsu, G. N. Hortobágyi(The University of Texas Medical Branch at Galveston), Antonio Giordano(University of Siena)

Journal of Clinical Oncology

May 20, 2011

10.1200/jco.2011.29.15_suppl.610

Cited by 1

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Curcumin and Cancer

|Nutrients|2019|977